Canada · Delayed Price · Currency is CAD Savaria Earnings Call Transcripts
Fiscal Year 2026
-
Record Q2 revenue of CAD 246 million, up 8.4% year-over-year, with strong growth in both accessibility and patient care. Adjusted EBITDA margin improved to 21.1%, and net earnings rose 54.4%. Strategic acquisitions and operational initiatives support a 12% annual growth target through 2030.
-
Q1 2026 saw 7% revenue growth to CAD 235.5 million and an 82% increase in net earnings, driven by operational improvements, strong European and North American performance, and successful Savaria One initiatives. Adjusted EBITDA margin rose to 20.4% and the company maintains a robust outlook for continued growth.
Fiscal Year 2025
-
Record Q4 and full-year results driven by strong growth in accessibility and patient care, improved margins, and operational efficiencies. European operations returned to growth, and capacity expansion plus strategic acquisitions position the company for continued momentum.
-
Record Q3 results with 21.2% adjusted EBITDA margin and 5.2% revenue growth, driven by operational improvements and strong Accessibility segment performance. Guidance for annual revenue and margins remains robust, with continued focus on growth, disciplined capital allocation, and strategic expansion.
-
Record Q2 margins and EBITDA were driven by operational efficiencies and new product launches, with revenue up 2.4% year-over-year. Guidance for 2025 remains strong, supported by a robust backlog, improved leverage, and ongoing strategic investments.
-
Record Q1 results with EBITDA up 17% and margin at 18.5%, driven by strong North American growth and operational efficiencies. Guidance for 2025 is maintained amid tariff uncertainty, with a robust backlog and new product launches supporting future growth.
Fiscal Year 2024
-
Q4 and 2024 results met expectations, with strong Patient Care growth and improved margins. 2025 guidance reflects tariff-related uncertainty, but management is confident in long-term margin recovery and growth, supported by operational improvements and a robust balance sheet.
-
Q3 saw record profitability with Adjusted EBITDA margin at 19.5% and strong North American growth, while Europe focused on margin gains. Cash flow and deleveraging improved, supporting future acquisitions and product launches.
-
Q2 2024 saw record revenue, gross profit, and Adjusted EBITDA, driven by double-digit organic growth in accessibility and strong operational execution. The company is on track for its 2025 targets, with healthy backlogs and ongoing margin improvements, especially in Europe.